METHOTREXATE EBEWE 100MG-ML 50ml VIAL

Product Overview

Benefits of Use

• Effective in treating a wide range of cancers, including leukemias, lymphomas, breast cancer, lung cancer, and osteosarcoma.
• Provides significant therapeutic benefit for severe, disabling psoriasis and active rheumatoid arthritis unresponsive to conventional therapies.
• High concentration allows for flexible dosing regimens tailored to individual patient needs and specific treatment protocols.
• Administered by healthcare professionals, ensuring precise dosage and monitoring during treatment.

How to Use

1. METHOTREXATE EBEWE 100MG/ML must be administered by a qualified healthcare professional with experience in oncologic or immunologic therapies.
2. The dosage, frequency, and route of administration (intravenous, intramuscular, or subcutaneous) are determined by the treating physician based on the patient's medical condition, body surface area, and specific treatment indication.
3. Strict adherence to the prescribed dosing schedule and comprehensive monitoring of the patient's response and potential side effects are crucial.
4. Patients undergoing high-dose methotrexate therapy often require concomitant leucovorin rescue to mitigate toxicity to healthy cells.
5. Ensure adequate hydration before and during administration, as advised by the healthcare provider.

Caution & Warnings

• Methotrexate therapy should only be initiated and supervised by physicians who are knowledgeable in the use of antimetabolite drugs and have experience with the specific indications.
• This medication carries a risk of severe and potentially fatal adverse reactions, including bone marrow suppression (leading to anemia, leukopenia, and thrombocytopenia), liver toxicity, kidney damage, and interstitial pneumonitis.
• Regular monitoring of complete blood counts, liver function tests, kidney function tests, and chest X-rays is essential throughout treatment.
• Methotrexate is teratogenic and embryotoxic; it is contraindicated in pregnancy and breastfeeding. Effective contraception is required for both male and female patients during treatment and for a specified period thereafter.
• Concomitant use with non-steroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors (PPIs) may increase methotrexate toxicity and should be avoided or closely monitored.
• Patients should immediately report any signs of infection, unexplained bleeding, severe gastrointestinal symptoms, or respiratory difficulties to their healthcare provider.

Ingredients

• Active Ingredient: Methotrexate (100 mg/mL)
• Excipients: (May include Sodium Chloride, Sodium Hydroxide/Hydrochloric Acid for pH adjustment, Water for Injection, depending on formulation).

Product Details

• Brand: Ebewe
• Form: Solution for Injection
• Strength: 100 mg/mL
• Package Size: 50 ml vial
• Manufacturer: Ebewe Pharma
• Therapeutic Class: Antineoplastic, Antirheumatic, Immunosuppressant